Vestmark Advisory Solutions’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$226K Buy
+598
New +$209K ﹤0.01% 1560
2023
Q2
– Sell
-421
Closed -$202K – 881
2023
Q1
$202K Buy
+421
New +$197K 0.01% 826
2022
Q2
– Sell
-547
Closed -$308K – 850
2022
Q1
$308K Buy
547
+107
+24% +$64.5K 0.02% 708
2021
Q4
$332K Buy
440
+13
+3% +$9.7K 0.02% 675
2021
Q3
$319K Buy
+427
New +$320K 0.02% 642
2020
Q3
– Sell
-751
Closed -$339K – 547
2020
Q2
$339K Sell
751
-155
-17% -$68.4K 0.05% 378
2020
Q1
$318K Buy
+906
New +$333K 0.06% 349
2019
Q4
– Sell
-1,006
Closed -$335K – 281
2019
Q3
$335K Sell
1,006
-1
-0.1% -$326 0.05% 386
2019
Q2
$315K Sell
1,007
-47
-4% -$14.1K 0.05% 392
2019
Q1
$322K Buy
+1,054
New +$284K 0.06% 378

Other funds holding BIO

Vestmark Advisory Solutions's BIO Position: Q3 2026 in Review

Vestmark Advisory Solutions opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 598 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #1560 among its holdings. This is a return to the name: Vestmark Advisory Solutions previously reported a position in BIO as recently as Q1 2023.

Vestmark Advisory Solutions first reported a position in BIO in Q1 2019 and has held it in 10 quarters since. The position peaked at $339K in Q2 2020. 386 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • Vestmark Advisory Solutions held 598 shares of Bio-Rad Laboratories Class A worth $226K as of Q3 2026.
  • Bio-Rad Laboratories Class A was a new Vestmark Advisory Solutions position in Q3 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Vestmark Advisory Solutions's portfolio in Q3 2026, its #1560 holding.
  • Vestmark Advisory Solutions first reported a position in Bio-Rad Laboratories Class A in Q1 2019 and has held it in 10 quarters since.
  • Vestmark Advisory Solutions's Bio-Rad Laboratories Class A position peaked at $339K in Q2 2020.
  • 386 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q3 2026, filed 16 Nov 2026.